CRO Charles River buys China's WuXi for $1.6B

Charles River Laboratories is wagering $1.6 billion that the future of contract research organizations lies in China. The Boston-based CRO announced early today that it has struck a deal to buy WuXi PharmaTech for $21.25 a share in cash and stock. Read more...